Literature DB >> 22118432

Intensified chemotherapy for diffuse large B-cell lymphomas.

Julie M Vose1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22118432     DOI: 10.1016/S0140-6736(11)61269-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  2 in total

1.  Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis.

Authors:  Santiago Montes-Moreno; Ana Batlle; Sonia González de Villambrosía; Beatriz Sánchez-Espiridión; Laura Cereceda; Eva González-Barca; Noelia Purroy; Emilia Pardal; Alejandro Martín; Carlos Grande; Francisco Mazorra; Andrés Insunza; Cristina Quero; David Aguiar; Miguel Angel Cruz; Antonio Rueda; Marta Llanos; José Gómez Codina; Francisco Ramón García Arroyo; Dolores Caballero; Eulogio Conde; Andrés López; Mariano Provencio; Miguel Piris
Journal:  Haematologica       Date:  2014-04-24       Impact factor: 9.941

2.  Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.

Authors:  Ana Batlle-López; Sonia González de Villambrosía; Mazorra Francisco; Sefora Malatxeberria; Anabel Sáez; Carlos Montalban; Lydia Sánchez; Juan Garcia; Eva González-Barca; Andrés López-Hernández; M C Ruiz-Marcellan; Manuela Mollejo; Carlos Grande; Kristy L Richards; Eric D Hsi; Alexandar Tzankov; Carlo Visco; Zijun Y Xu-Monette; Xin Cao; Ken H Young; Miguel Ángel Piris; Eulogio Conde; Santiago Montes-Moreno
Journal:  Oncotarget       Date:  2016-04-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.